Skip to main content

Advertisement

SpringerLink
Log in

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in recurrent epithelial ovarian cancer with peritoneal metastases: a single centre experience

  • Original Article
  • Published:
Langenbeck's Archives of Surgery Aims and scope Submit manuscript

Abstract

Background

This investigation aims to assess morbidity, mortality and postoperative outcomes of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer (REOC) with peritoneal metastases (PM).

Methods

Consecutive patients with radiographic evidence of REOC with PM were scheduled for CRS and HIPEC at the Comprehensive Cancer Center, University Hospital Tübingen, Germany. Clinical data were retrospectively analyzed.

Results

In total, 90 patients were analyzed. Complete cytoreduction and HIPEC could be performed in 69 % of patients. When categorizing patients with respect to the completeness of cytoreduction (CC-0/1 vs CC-2/3), there was no difference considering baseline demographic characteristics. Cumulative morbidity was 42 %. Morbidity rates did not statistically differ between CC-0/1 patients with HIPEC and CC-2/3 patients without HIPEC. No surgery-related and 90-day postoperative mortality was observed. In CC-0/1 patients, median overall survival was 35 months as opposed to 14 months in CC-2/3 patients. There was no difference in survival with respect to the peritoneal carcinomatosis index (PCI) as long as complete cytoreduction could be achieved.

Conclusions

CRS and HIPEC can be performed with acceptable morbidity and low mortality in specialized centres. Our data do not suggest that HIPEC necessarily increases the risk of postoperative adverse events.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Tropé C, CON, AGO Collaborators (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361:2099–2106

    Article  CAS  PubMed  Google Scholar 

  2. Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, Wagner U, Stähle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, Lück HJ, Rochon J, Zimmermann AH, Eisenhauer E (2006) Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24:4699–4707

    Article  CAS  PubMed  Google Scholar 

  3. Hennessy BT, Coleman RL, Markman M (2009) Ovarian cancer. Lancet 374:1371–1382

    Article  CAS  PubMed  Google Scholar 

  4. Harter P, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S et al (2006) Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 13:1702–1710

    Article  PubMed  Google Scholar 

  5. Harter P, Hahmann M, Lueck HJ, Poelcher M, Wimberger P, Ortmann O et al (2009) Surgery for recurrent ovarian cancer: role of peritoneal carcinomatosis: exploratory analysis of the DESKTOP I trial about risk factors, surgical implications, and prognostic value of peritoneal carcinomatosis. Ann Surg Oncol 16:1324–1330

    Article  CAS  PubMed  Google Scholar 

  6. Alberts DS, Liu PY, Hannigan EV, O’Toole R, Williams SD, Young JA et al (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus inrtavenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950–1955

    Article  CAS  PubMed  Google Scholar 

  7. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S et al (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34–43

    Article  CAS  PubMed  Google Scholar 

  8. Jaaback K, Johnson N, Lawrie TA (2011) Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev.; 9;(11)

  9. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H et al (2003) Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 21:3737–3743

    Article  PubMed  Google Scholar 

  10. Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B et al (2010) Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric french study. J Clin Oncol 28:63–68

    Article  PubMed  Google Scholar 

  11. Bakrin N, Bereder JM, Decullier E et al (2013) Peritoneal carcinomatosis treated with cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol 39:1435–1443

    Article  CAS  PubMed  Google Scholar 

  12. Helm CW (2009) The role of hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. Oncologist 14:683–694

    Article  CAS  PubMed  Google Scholar 

  13. Piso P, Dahlke MH, Loss M, Schlitt HJ (2004) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer. World J Surg Oncol 2:21

    Article  PubMed Central  PubMed  Google Scholar 

  14. Di Giorgio A, Naticchioni E, Biacchi D, Sibio S, Accarpio F, Rocco M et al (2008) Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer 113:315–325

    Article  PubMed  Google Scholar 

  15. Helm CW, Randall-Whitis L, Martin RS III, Metzinger DS, Gordinier ME, Parker LP et al (2007) Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma. Gynecol Oncol 105:90–96

    Article  CAS  PubMed  Google Scholar 

  16. Spiliotis J, Vaxevanidou A, Sergouniotis F, Lambropoulou E, Datsis A, Christopoulou A (2011) The role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent advanced ovarian cancer: a prospective study. J BUON 16:74–79

    CAS  PubMed  Google Scholar 

  17. Chua TC, Liauw W, Robertson G, Chia WK, Soo KC, Alobaid A et al (2009) Towards randomized trials of cytoreductive surgery using peritonectomy and hyperthermic intraperitoneal chemotherapy for ovarian cancer peritoneal carcinomatosis. Gynecol Oncol 114:137–139

    Article  PubMed  Google Scholar 

  18. Harter P, Mahner S, Hilpert F, Runnebaum I, Ortmann O, Mustea A, Sehouli J, du Bois A, Wagner U (2013) Statement by the Kommission OVAR of the AGO study group on the use of HIPEC to treat primary and recurrent ovarian cancer. Geburtsh Frauenheilk 73:221–223

    Article  PubMed Central  PubMed  Google Scholar 

  19. Jaquet P, Sugarbaker PH (1996) Current methodologies for clinical assessment of patients with peritoneal carcinomatosis. J Exp Clin Cancer Res 15:49–58

    Google Scholar 

  20. Sugarbaker PH (1995) Peritonectomy procedures. Ann Surg 221:29–42

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Dindo D, Demartines N, Clavien PA (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213

    Article  PubMed Central  PubMed  Google Scholar 

  22. Raspagliesi F, Kusamura S, Campos Torres JC, de Souza GA, Ditto A, Zanaboni F et al (2006) Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: the experience of National Cancer Institute of Milan. Eur J Surg Oncol 32:671–675

    Article  CAS  PubMed  Google Scholar 

  23. Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA et al (2009) Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 114:26–31

    Article  PubMed  Google Scholar 

  24. Königsrainer I, Beckert S, Becker S, Zieker D, Fehm T, Grischke EM, Lauk O, Glatzle J, Brücher B, Wallwiener D, Königsrainer A (2011) Cytoreductive surgery and HIPEC in peritoneal recurrent ovarian cancer: experience and lessons learned. Langenbecks Arch Surg 396:1077–1081

    Article  PubMed  Google Scholar 

  25. Hyperthermic intra-peritoneal chemotherapy (hipec) in relapse ovarian cancer treatment (CHIPOR); http://clinicaltrials.gov/show/NCT01376752

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of General, Visceral and Transplant Surgery, University of Tübingen, Comprehensive Cancer Center, Hoppe-Seyler-Strasse 3, 72076, Tübingen, Germany

    Ingmar Königsrainer, Philipp Horvath, Florian Struller, Alfred Königsrainer & Stefan Beckert

  2. Department of Gynecology, University of Tübingen, Comprehensive Cancer Center, Calwerstrasse 7, 72076, Tübingen, Germany

    Eva Maria Grischke & Diethelm Wallwiener

Authors
  1. Ingmar Königsrainer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Philipp Horvath
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Florian Struller
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eva Maria Grischke
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Diethelm Wallwiener
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alfred Königsrainer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Stefan Beckert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ingmar Königsrainer.

Additional information

This manuscript contains original material that has not been previously published.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Königsrainer, I., Horvath, P., Struller, F. et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in recurrent epithelial ovarian cancer with peritoneal metastases: a single centre experience. Langenbecks Arch Surg 399, 589–594 (2014). https://doi.org/10.1007/s00423-014-1207-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00423-014-1207-5

Keywords

Search

Navigation